• Image of Enablex medication Image of Enablex medication
    • DARIFENACIN ER

    • QTY 90
    • 15 MG
    • Tablet ER 24H
    • Near  43215

DARIFENACIN (dar ee FEN a sin) is used to treat overactive bladder. This medicine reduces the amount of bathroom visits. It may also help to control wetting accidents.


DARIFENACIN ER Lifestyle Interactions

  • Darifenacin 15mg, Oral tablet, extended release

    Interaction: Caffeine-containing Foods/Beverages
    Severity: Mild
    Notes for Consumers: The intake of beverages containing caffeine may decrease the actions of Darifenacin because Caffeine may increase urination. You may wish to limit your caffeine intake (including intake of coffee, colas, teas, or herbal supplements) while taking Darifenacin.
    Notes for Professionals: Consuming > 400 mg/day caffeine has been associated with the development of urinary incontinence. Caffeine may aggravate bladder symptoms and counteract the effectiveness of darifenacin to some degree. Patients may wish to limit their intake of caffeinated drugs, dietary supplements (e.g., guarana), or beverages (e.g., green tea, other teas, coffee, colas).
  • Darifenacin 15mg, Oral tablet, extended release

    Interaction: Grapefruit juice
    Severity: Moderate
    Notes for Consumers: Side effects from Darifenacin may get worse if you take grapefruit juice. Do not significantly alter your intake of grapefruit or grapefruit juice while taking Darifenacin. Discuss any new or worsening side effects, such as constipation, dizziness, difficulty with urination, dry mouth and eyes, changes in vision, fast heartbeat, or confusion, with your health care provider.
    Notes for Professionals: Advise patients that grapefruit juice may increase darifenacin plasma concentrations resulting in increased adverse effects. Darifenacin is a CYP3A4 substrate; grapefruit juice is a strong CYP3A4 inhibitor. The manufacturer of darifenacin recommends a maximum daily dose of 7.5 mg of darifenacin if coadministered with a strong CYP3A4 inhibitor.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.